Want to see SOPH full AI Analyst Report?
Top Page
SOPHiA GENETICS
(NASDAQ:SOPH)
Select Model
Select Model
Rating:54Neutral
Price Target:
$8.00
▲(39.86% Upside)
Action:Reiterated
Date:08/10/26
The score is held back primarily by weak financial performance (large operating losses and sustained cash burn) and loss-driven valuation uncertainty. These are partially offset by a positive earnings-call outlook (raised revenue guidance, improving adjusted EBITDA trajectory, strengthened cash position) and supportive technical trend, though the stock appears overbought.
Positive Factors
Revenue Growth & Guidance
Management raised FY26 revenue guidance after Q2 revenue of $23.3M (+27% YoY), reflecting durable demand for the usage/subscription platform. Sustained volume-driven growth increases recurring revenue visibility and supports scaling investments over the next 2–6 months and beyond.
Negative Factors
Cash Burn & Free Cash Flow Deficit
Persistent negative operating and free cash flow indicate the business is not yet self-funding. Even with a recent $57.5M raise, ongoing cash burn keeps financing risk elevated and makes multi-quarter investment pacing and runway dependent on continued capital access or faster margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Guidance
Management raised FY26 revenue guidance after Q2 revenue of $23.3M (+27% YoY), reflecting durable demand for the usage/subscription platform. Sustained volume-driven growth increases recurring revenue visibility and supports scaling investments over the next 2–6 months and beyond.
Read all positive factors
SOPHiA GENETICS Key Performance Indicators (KPIs)
Any
Revenue by Segment
Reveals which parts of SOPHiA GENETICS’ business—such as platform subscriptions, consumables or services—are generating sales and profits. A large share of recurring platform revenue suggests steadier cash flow and scalable growth, while dependence on one-time product sales or a single segment increases volatility and margin risk.
Reveals which parts of SOPHiA GENETICS’ business—such as platform subscriptions, consumables or services—are generating sales and profits. A large share of recurring platform revenue suggests steadier cash flow and scalable growth, while dependence on one-time product sales or a single segment increases volatility and margin risk.
Data provided by:
The Fly
The FlySOPHiA GENETICS (SOPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$646.83M
Dividend YieldN/A
Average Volume (3M)100.95K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth23.65%
EPS Growth-4.80%
CountryUS
Employees415
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-1.15
Shares Outstanding83,895,260
10 Day Avg. Volume137,858
30 Day Avg. Volume100,949
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)6.69
Price to Sales (P/S)4.08
P/FCF Ratio-8.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside74.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$93.38M
SOPHiA GENETICS Business Overview & Revenue Model
Company Description
SOPHiA GENETICS (SOPH) is a healthcare technology company that provides a cloud-based software and data analytics platform used by clinical laboratories and hospitals to analyze complex medical data—primarily genomic sequencing data—to support cli...
How the Company Makes Money
SOPHiA GENETICS generates revenue primarily by selling access to its cloud-based analytics platform and related software applications to healthcare providers (e.g., hospitals and clinical laboratories). The company’s revenue model is generally usa...
SOPHiA GENETICS Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call presented a strongly positive operational and commercial narrative: accelerating top-line growth (27% YoY), record analysis volumes (+22%), exceptional U.S. momentum (U.S. revenue +64%), materially improved adjusted EBITDA (27% improvement) and strategic, value-creating partnerships (AstraZeneca CDx wins and MSK JV MOU). These positives were balanced against margin pressure from growing pharma and services revenue, one-off legal and restructuring costs, an implementation backlog, and the fact the company remains adjusted EBITDA negative for 2026. On balance, the strategic wins, raised guidance, improved operating leverage, and a strengthened cash position outweigh the near-term margin and legal/headcount transition headwinds.Positive Updates
Revenue Growth and Guidance Raise
Total revenue of $23.3M in Q2, up 27% year-over-year (from $18.3M). Company raised full-year 2026 revenue guidance to $94M–$96M (22%–24% growth), up from prior guide of $92M.
Negative Updates
Gross Margin Compression
Reported gross margin declined to 64.6% from 67.0% year-over-year (down ~240 bps). Adjusted gross margin declined to 72.1% from 74.4% (down ~230 bps), primarily driven by increased biopharma projects and services that carry lower initial margins and higher cloud/AI compute and new-region infrastructure costs.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Guidance Raise
Total revenue of $23.3M in Q2, up 27% year-over-year (from $18.3M). Company raised full-year 2026 revenue guidance to $94M–$96M (22%–24% growth), up from prior guide of $92M.
Read all positive updates
Company Guidance
SOPHiA raised full‑year 2026 revenue guidance to $94–$96M (up 22%–24% YoY, vs prior $92M), while reaffirming full‑year adjusted EBITDA loss of $29–$32M (vs $41.5M in FY2025), expecting to approach adjusted‑EBITDA breakeven by YE2026 and turn positive in 2H2027. The raise is supported by Q2 results: revenue $23.3M (+27% YoY), 115,000 analyses (+22% YoY), adjusted EBITDA loss $8.8M (improved 27% YoY), U.S. revenue +64%/volume +60%, liquid‑biopsy revenue +80%, net dollar retention 117%, churn <1%, 542 core genomic customers (24 added in Q2), $107.7M cash after a ~$57.5M offering, and >$100M pipelines.SOPHiA GENETICS Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.17M | 77.27M | 65.17M | 62.37M | 47.56M | 40.45M |
| Gross Profit | 57.41M | 47.81M | 43.94M | 42.91M | 31.25M | 25.22M |
| EBITDA | -65.11M | -64.40M | -50.76M | -69.57M | -81.38M | -69.24M |
| Net Income | -80.88M | -79.00M | -62.49M | -78.98M | -87.45M | -73.67M |
Balance Sheet | ||||||
| Total Assets | 198.36M | 163.46M | 155.31M | 206.16M | 243.84M | 320.17M |
| Cash, Cash Equivalents and Short-Term Investments | 107.67M | 70.29M | 80.23M | 123.25M | 178.61M | 265.32M |
| Total Debt | 61.83M | 63.02M | 30.03M | 18.60M | 16.74M | 13.06M |
| Total Liabilities | 115.24M | 116.31M | 58.82M | 54.71M | 43.71M | 44.77M |
| Stockholders Equity | 83.12M | 47.15M | 96.49M | 151.44M | 200.13M | 275.40M |
Cash Flow | ||||||
| Free Cash Flow | -45.63M | -38.59M | -51.00M | -57.80M | -80.47M | -64.61M |
| Operating Cash Flow | -41.60M | -38.01M | -42.82M | -48.58M | -70.09M | -57.94M |
| Investing Cash Flow | -11.84M | -10.51M | -8.18M | 8.32M | 41.97M | -56.93M |
| Financing Cash Flow | 66.79M | 34.13M | 11.59M | -2.82M | -1.57M | 237.77M |
SOPHiA GENETICS Technical Analysis
Positive
5.72
Price Trends
5.67
Positive
5.31
Positive
5.02
Positive
Market Momentum
0.40
Negative
70.90
Negative
84.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOPH, the sentiment is Positive. The current price of 5.72 is below the 20-day moving average (MA) of 6.16, above the 50-day MA of 5.67, and above the 200-day MA of 5.02, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 70.90 is Negative, neither overbought nor oversold. The STOCH value of 84.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SOPH.
SOPHiA GENETICS Risk Analysis
SOPHiA GENETICS disclosed 1 risk factors in its most recent earnings report. SOPHiA GENETICS reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SOPHiA GENETICS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $1.41B | 368.04 | 1.84% | ― | 47.63% | ― | |
60 Neutral | $2.30B | -21.40 | -38.72% | ― | 25.42% | -10900.00% | |
55 Neutral | $1.36B | -25.36 | -16.37% | ― | 8.88% | 70.36% | |
54 Neutral | $646.83M | -6.67 | -140.63% | ― | 23.65% | -4.80% | |
52 Neutral | $102.57M | -0.44 | -74.75% | ― | -3.89% | 63.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $1.25M | >-0.01 | -32.44% | ― | -28.30% | -86.74% |
* Healthcare Sector Average
SOPH
SOPHiA GENETICS
7.67
4.53
144.27%
SDGR
Schrodinger
18.77
-0.08
-0.42%
ZCMD
Zhongchao
1.14
-713.84
-99.84%
WGS
GeneDx Holdings
77.88
-38.53
-33.10%
DH
Definitive Healthcare Corp
0.70
-2.90
-80.58%
OMDA
Omada Health, Inc.
24.99
5.70
29.55%
SOPHiA GENETICS Corporate Events
SOPHiA GENETICS Updates Investors With Q2 2026 Form 6-K Filing
Aug 4, 2026
On August 4, 2026, SOPHiA GENETICS SA filed a Form 6-K with the U.S. Securities and Exchange Commission for August 2026, reinforcing its reporting obligations as a foreign private issuer. The filing, signed by Chief Legal and Regulatory Officer Da...
SOPHiA GENETICS Raises $57.5 Million in June 2026 Share Offering
Jun 22, 2026
On June 16, 2026, SOPHiA GENETICS entered into an underwriting agreement to sell 12,104,900 ordinary shares at $4.75 each, including the full exercise of the underwriters’ option, raising gross proceeds of about $57.5 million. The U.S.-regis...
SOPHiA GENETICS Shareholders Back 2025 Results, Board Line-Up and Capital Changes at June 18 AGM
Jun 22, 2026
On June 18, 2026, SOPHiA GENETICS SA held its annual general meeting, where shareholders overwhelmingly approved the 2025 management report, annual and consolidated financial statements, and the ESG Impact Summary, while discharging the board and ...
SOPHiA GENETICS and MSK Forge Joint Venture MOU to Build Global Precision Oncology Hub
Jun 4, 2026
On June 4, 2026, SOPHiA GENETICS announced it had signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture focused on next-generation precision oncology. The planned precision medicine hub would marr...
SOPHiA GENETICS Files Form 6-K and Publishes 2025 ESG Impact Summary
May 19, 2026
On May 19, 2026, SOPHiA GENETICS SA reported that it has published its Environmental, Social and Governance Impact Summary as of December 31, 2025. The 2025 ESG Impact Summary, made available through the company’s investor relations site, ou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.